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Abstract 
Background: Bronchiolitis is one of the most common lower respiratory tract infections in children and its 
incidence varies from country to country with studies reporting up to 18% of total admissions due to bronchiolitis 
with most of the cases occurring during winter. In our study we compare efficacy of nebulised 3% hypertonic 
saline with 0.9% normal saline for treatment of acute bronchiolitis in children up to 2 years of age in terms of 
mean days of hospital stay and clinical severity score. 
Methods: This Randomized controlled trial (RCT) was done in department of Paediatrics, POF Hospital Wah 
Cantt from 1st November 2015 to 31st March 2016. Children in group 1 were nebulized with 3% hypertonic saline 
and group 2 with 0.9% normal saline.  
Results: In group 1 the mean clinical severity score at the time of admission was 8.46 + 1.10 and in group 2, 8.7 + 
0.98. In group 1 the mean clinical severity score after 3 days was 2.7 + 0.87 and in group 2, 4.4 + 0.999. The mean 
length of hospital stays for group 1 was 4.23 days + 1.2 and in group 2 it was 6.4 days + 1.4. Mean of clinical 
clarity score after 3 days and mean of length of hospital stay was compared between both groups for which the p 
value was significant. 
Conclusion: Hypertonic saline (HS) nebulization has shown improved outcome in bronchiolitis. More studies are 
required to see the outcome of this method of treatment. 
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Introduction 
 
Bronchiolitis is one of the most common lower 
respiratory tract infections in children and its 
incidence varies from country to country with studies 
reporting up to 18% of total admissions 1 due to 
bronchiolitis with most of the cases occurring during 
winter2. There is no consensus on definition of 
bronchiolitis but American Academy of Pediatrics 
(AAP) have defined it as “a constellation of clinical 
symptoms and signs including a viral upper 
respiratory prodrome followed by increased 
respiratory effort and wheezing in children less than 2 
years of age" 3. Respiratory syncytial virus (RSV) is the 
most common virus causing bronchiolitis 4 followed 
by Rhinovirus , human boca virus , human 
metapneumo virus, entero, adeno, corona and 
Influenza viruses 5, 6.  
Clinically bronchiolitis presents with cough, 
rhinorrhea, fever, feeding problems, tachypnoea, 
wheezing and fine inspiratory crackles on auscultation 
7, 8. Optimal treatment of acute bronchiolitis is 
controversial and includes therapies like supportive 
care 9, 10, racemic adrenaline 11, salbutamol 12, 
nebulized normal saline, nebulized hypertonic saline 
13 and corticosteroids 14. Recent studies have shown 
beneficial effect of nebulization with 3% hypertonic 
saline (HS) as compared to 0.9 % normal saline (NS) 
nebulization 15. 
Acute respiratory illness (ARI) is one of the leading 
causes of death in young children in Pakistan with 
around 30% of these deaths occurring under age 5 
years 16. Currently there is limited published data 
regarding use of 3% HS for the management of acute 
bronchiolitis in Pakistan. Thus this study was done to 
investigate the efficacy of nebulised 3% HS compared 
to 0.9% NS for the management of acute bronchiolitis 
in children under 2 years of age. 
 
Material and Methods 
This Randomized Control Trail (RCT) was done in 
department of Paediatrics, POF Hospital Wah Cantt 
over a period of six months from 1st November 2015 to 
31st March 2016 after the approval of ethical committee 
of hospital. Sample size was calculated by using WHO 
formula with following values: 
• Level of significant = 5% 
• Power of test = 90% 
• Population mean15 = 2.4 
• Anticipated mean15 = 4.1 
• Pooled standard deviation = 1 
Required sample size was 30 children with acute 
bronchiolitis in each group. Non-Probability Sampling 
technique was used in this study. 
Inclusion Criteria: 
• All children aged up to 2 years with first 
episode of acute wheezing following upper 
respiratory tract infection with clinical 
severity score of 0-8 and SpO2 < 94% at room 
air. 
Exclusion Criteria: 
• History of recurrent wheezing 
• Congenital Heart Disease 
• Severe Disease at presentation or respiratory 
failure 
• Use of nebulized hypertonic saline within 
previous 12 hours 
• Premature birth (gestational age ≤ 34 weeks) 
• Radiological evidence of pneumonia including 
infiltrates / consolidation 
Operational Definitions: 
3% Hypertonic Saline 
3% hypertonic saline contains 30 g/L of NaCl with 
ionic concentrations of Sodium and Chloride equal to 
513 mEq/L, osmolarity of 1027 mOsmol/L and PH of 
5.0 (4.5 to 7.0). 4 ml was given per dose in nebulised 
form. 
0.9% Normal Saline: 
Normal saline contains 9 g/L of NaCl with ionic 
concentrations of Sodium and Chloride equal to 154 
mEq/L and PH of 5.0 (4.5 to 7.0 ). 4 ml was given per 
dose in nebulised form. 
Clinical Severity Scores 
The clinical score was calculated as shown 15 (Table 1): 
Table 1: Clinical severity score: 
VARIABLE 0 POINT 1 POINT 2 POINT 3 
POINT 
Respiratory 
Rate 
< 30 
breaths/m
in 
31-45 
breaths/m
in 
breaths/mi
n 
>60 
breaths
/min 
Wheezing None  terminal 
expiratory 
or heard 
only with 
a 
stethoscop
e 
entire 
expiration 
or audible 
on 
expiration 
without a 
stethoscop
e 
inspirati
on and 
expirati
on 
without 
a 
stethosc
ope 
Retractions None Intercostal 
only 
Tracheoste
rnal 
Severe 
with 
nasal 
flaring. 
General 
condition 
Normal  Irritable lethargic Poor 
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feeding 
The clinical total score ranks as: 
• 0–4.9 points, mild;  
• 5–8.9 points, moderate; and  
• 9–12 points, severe disease 
Data Collection Procedure: After taking informed 
consent from parents /guardians all children up to 2 
years of age fulfilling the above-mentioned inclusion 
criteria with diagnosis of acute bronchiolitis were 
enrolled in the study. A computer-generated table of 
random numbers were used to randomize the enrolled 
children into two groups, as group 1 for 3% HS and 
group 2 for 0.9% NS. Demographic features such as 
age and gender were noted on a specially designed 
performa. Children in both groups, group 1 and 2, 
were subjected to chest X-ray. In group 1 nebulisation 
with 4ml of 3% HS was given every 2 hours for 3 
doses, followed by every 4 hours for 5 doses, followed 
by every 6 hours until discharge. Group 2 received 
nebulisation with 4ml of 0.9% NS at similar intervals 
as HS. 
Clinical severity scores were calculated at the time of 
admission (baseline) and then the final clinical severity 
scores were calculated on the 3rd day of admission. 
The total length of hospital stay was recorded from 
day of admission to day of discharge. All inhaled 
therapies were delivered to children from standard 
oxygen driven hospital nebuliser through a tight-
fitting face mask. Discharge criteria was clinical 
severity scores of < 4 and SpO2 ≥ 95% at room air. 
Data Analysis Procedure: The data was entered and 
analysed using SPSS version 18. For continuous 
variables such as age, length of hospital stays and 
clinical severity score, mean ± SD were calculated. 
Frequencies and percentages were measured for 
categorical variables such as gender. To compare mean 
clinical severity score and mean length of hospital stay 
between the two groups, 3% HS and 0.9% NS, 
independent two sample Student t test were used and 
p-values was obtained. P value ≤ 0.05 was considered 
as significant. 
 
Result 
Total of 60 patients were included in the study with 
each group comprising 30 patients. Mean age of the 
patients included in the study was 12.1 + 4.97. Mean 
age in group 1 was 12.5 months with minimum age 4 
months maximum 21 months and STD + 4.9. In group 
2 mean age was 11.8 months with minimum age 4 
months maximum 22 months and STD + 5.08. There 
was predominance of males in the study. Comparison 
of both the groups is shown in Table 2. 
 
Table 2: Comparison of Clinical Information Of 
Groups 
VARIABLES GROUP 1  
(HS 
GROUP) 
(n-30)  
GROUP 2  
NS 
GROUP 
(n-30)  
SEX: 
Male 
Female 
 
18 (60 %) 
10 (40 %) 
 
19 (63 %)   
11 (37 %) 
CATEGORIES OF AGE: 
1 – 6 months 
7 – 12 months 
13 – 18 months 
19 – 24 months 
 
5 (16.6 %) 
9 (30 %) 
12 (40 %) 
4 (13.3 %) 
 
6 (20 %) 
9 (30 %) 
12 (40 %) 
3 (10 %) 
MEAN CLINICAL 
SEVERITY SCORE 
8.46 + 1.10 8.7  + 0.98 
CLINICAL CATEGORY 
Moderate  
Severe  
 
15 (50 %) 
15 (50 %) 
 
13 (43.3 %) 
17 (56.6 %) 
  
At the time of admission, minimum clinical severity 
score in group 1 was 6 whereas in group 2 it was 7. 
Maximum clinical scores were 10 and 11 in group 1 
and group 2 respectively. After 3 days of treatment, 
minimum clinical severity in group 1 was 1 and 
maximum score was 5 whereas in group 2 minimum 
clinical score was 3 and maximum was 7. Comparison 
of both groups after treatment is shown in table 3. 
 
Table 3: Comparison Of Groups After Treatment 
VARIABLES GROUP 1 
(n-30) 
Group 2 
(n-30) 
P 
value 
MEAN CLINICAL 
SEVERITY SCORE 
2.7 + 0.87 4.4 + .99 0.0001 
MEAN LENGTH OF 
HOSPITAL STAY 
4.23 + .27 6.43 + .43 0.0001 
 
After 3 days of treatment, 28 (93 %) patients from 
group 1 and 17 (57%) patients from group 2 were 
classified as having mild clinical disease whereas 2 
(7%) from group 1 and 13 (43%) from group 2 had 
moderate clinical disease.  
Stratification of clinical severity score with respect to 
age category showed that in 1-6 months category; in 
group 1 mean score was 2.800 + 0.447 while in group 2 
mean score was 4.000 + 0.632. P-value was 0.006. In 7-
12 months category; group 1 had mean score of 3.00 + 
0.866 and group 2 had mean score of 4.333 + 1.322. P-
value was 0.022. In 13-18 months category mean score 
was 2.667 + 1.073 in group 1 and 4.75 + 0.866 in group 
2. P-value was 0.001. In 19-24 months category; 2.25 + 
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0.50 was mean score in group 1 and 3.67 + 0.577 was 
mean score in group 2. P-value was 0.018. 
Stratification results of clinical severity score with 
respect to gender and clinical category at admission 
are shown in Table 4: 
 
TABLE 4: Stratification of mean Clinical Severity 
Score after treatment 
VARIABLE MEAN 
CLINICAL  
SEVERITY 
SCORE 
GROUP 1 
MEAN 
CLINICAL  
SEVERITY 
SCORE 
GROUP 2 
p 
VALUE 
GENDER: 
• Male 
• Female 
 
3 + 0.97 
2.33 + 0.49 
 
4.42 + 1.12 
4.27 + 0.78 
 
0.0001 
0.0001 
CLINICAL 
CATEGORY  
AT ADMISSION: 
• Moderate  
• Severe 
 
 
 
2.13 + 0.51 
3.33 + 0.72 
 
 
 
3.61 + 0.65 
4.94 + 0.82 
 
 
 
0.0001 
0.0001 
 
Stratification of length of hospital stay with respect to 
age category showed that in 1-6 months category; in 
group 1 mean length of hospital stay was 4.200 + 0.836 
while in group 2 mean length of hospital stay was 
6.333 + 1.032. P-value was 0.005. In 7-12 months, 
category; group 1 had mean length of hospital stay of 
4.444 + 1.509 and group 2 had mean length of hospital 
stay of 6.333 + 2.000. P-value was 0.038. In 13-18 
months, category mean length of hospital stay was 
4.250 + 1.484 in group 1 and 6.500 + 1.314 in group 2, 
P-value was 0.0001. In 19-24 months, category 3.750 + 
0.500 was mean length of hospital stay in group 1 and 
6.667 + 1.154 was mean length of hospital stay in 
group 2. P-value was 0.006. Stratification results of 
length of hospital stay with respect to gender and 
clinical category at admission are shown in Table 5: 
 
VARIABLE MEAN 
LENGTH 
OF STAY 
GROUP 1 
MEAN 
LENGTH OF 
STAY 
GROUP 2 
P 
VALUE 
GENDER: 
Male 
Female 
 
4.56 + 1.46 
3.75 +  0.75 
 
6.42 + 1.46 
6.45 + 1.43 
 
0.0001 
0.0001 
CLINICAL 
CATEGORY  
AT 
ADMISSION: 
Moderate 
Severe 
 
 
 
 
3.46 + 0.51 
5.00 + 1.36 
 
 
 
 
5.38 + 1.04 
7.23 + 1.14 
 
 
 
 
0.0001 
0.0001 
TABLE 5: Stratification of mean length of hospital 
stay after treatment 
 
Discussion 
Bronchiolitis is a common respiratory tract infection in 
children whose treatment is still controversial. 
Nebulizations with various saline compositions have 
been found to be an effective treatment in literature 
and in this study we compared hypertonic saline 
nebulization with normal saline nebulisations.  
In our study, mean age was 12.1 + 4.97 months which 
is high as compared to Ahmad 17 and had 
predominance of males which was also shown by local 
studies 16, 17 and a Nepalese study which was a double 
blind controlled trial with similar sample size and age 
group 18. This male predominance may be due to 
gender specific immune response to RSV infection 19. 
Baseline characters of both the groups were same in 
our study. Patients nebulized with hypertonic saline 
had early resolution of symptoms as compared to the 
other group. This effectiveness of hypertonic saline 
nebulization has also been found by Luo et al in their 
prospective, randomized, single centre, double-blind 
controlled study 15. Ejaz et al 20 in their study had 
documented that HS nebulization had resulted in 
decrease of clinical severity score in lesser time as 
compared to NS nebulization which is also present in 
our study. Due to the effectiveness of HS nebulization, 
clinicians have used it in patients presenting in 
emergency department which have resulted in 
decrease in hospital admissions and early discharge 
from out- patient department resulting in decrease 
hospital burden 21, 22.On the contrary, Florin et al 23 in 
their study did not find improved outcome of HS 
nebulization in emergency settings. Our study did not 
measure this outcome but can be done in future trials. 
Effect of HS nebulization on length of hospital stay 
had been a topic of interest for various researchers. In 
our study, the hospital stay of the patients who 
received HS nebulization was significantly reduced as 
compared to those who received NS nebulization as 
also shown by Cochrane review 24.On other hand; 
Silver et al25 in their study which was done in a 
tertiary care hospital and Brooks et al 26 in their meta-
analysis were unable to find any statistical effect of 
nebulization on the stay of the patients suffering from 
acute bronchiolitis. Their inference may be because of 
the reason that these studies enrolled only children 
under 1 year of age and our sample included children 
up to 2 years of age.  
Bronchiolitis is a common cause of respiratory illness 
requiring hospital admission in our setup. Ours was a 
well-designed randomized control trial with blinding 
maintained throughout the study period to minimize 
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the bias. A previously validated clinical criteria 
scoring was used to assess the clinical response.  This 
study showed early improvement and less stay in 
hospital in patients treated with hypertonic saline 
which was also found in national and international 
studies thus proving to be a better treatment modality. 
There were few limitations of our study. It was a 
single centred study and also had a small sample size. 
Another limitation was that in clinical response we did 
not check for the relapse in these cases. 
 
Conclusion 
Bronchiolitis is one of common respiratory 
emergencies encountered in paediatric emergency. 
Different methods of treatment have been suggested 
throughout the world. Use of hypertonic saline in 
treatment of children has shown improved outcome in 
our study. More randomized multicentre control 
studies with larger sample size should be carried out 
to see the outcome of this method of treatment. 
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